Limits...
TRIM29 as a novel biomarker in pancreatic adenocarcinoma.

Sun H, Dai X, Han B - Dis. Markers (2014)

Bottom Line: TRIM29 protein expression was significantly correlated with lymph node metastasis (P = 0.019).Patients with positive TRIM29 expression showed both shorter overall survival and shorter recurrence-free survival than those with negative TRIM29 expression.Our results indicate that TRIM29 promotes tumor progression and may be a novel prognostic marker for pancreatic ductal adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Biliary and Vascular Surgery, Shengjing Hospital of China Medical University, Heping District, Shenyang 110004, China.

ABSTRACT

Background and aim: Tripartite motif-containing 29 (TRIM29) is structurally a member of the tripartite motif family of proteins and is involved in diverse human cancers. However, its role in pancreatic cancer remains unclear.

Methods: The expression pattern of TRIM29 in pancreatic ductal adenocarcinoma was assessed by immunocytochemistry. Multivariate logistic regression analysis was used to investigate the association between TRIM29 and clinical characteristics. In vitro analyses by scratch wound healing assay and invasion assays were performed using the pancreatic cancer cell lines.

Results: Immunohistochemical analysis showed TRIM29 expression in pancreatic cancer tissues was significantly higher  (n = 186) than that in matched adjacent nontumor tissues. TRIM29 protein expression was significantly correlated with lymph node metastasis (P = 0.019). Patients with positive TRIM29 expression showed both shorter overall survival and shorter recurrence-free survival than those with negative TRIM29 expression. Multivariate analysis revealed that TRIM29 was an independent factor for pancreatic cancer over survival (HR = 2.180, 95% CI: 1.324-4.198, P = 0.011). In vitro, TRIM29 knockdown resulted in inhibition of pancreatic cancer cell proliferation, migration, and invasion.

Conclusions: Our results indicate that TRIM29 promotes tumor progression and may be a novel prognostic marker for pancreatic ductal adenocarcinoma.

Show MeSH

Related in: MedlinePlus

TRIM29 is overexpressed in the pancreatic cancer cells by immunohistochemical analysis. (a) Adjacent nontumor pancreatic duct (NPD) is indicated. (b) Malignant pancreatic duct shows nuclear TRIM29 staining, whereas adjacent pancreatic ductal cells show negative staining. Pancreatic cancer cells (PC) are indicated. (c) TRIM29 staining in poorly differentiated pancreatic adenocarcinoma. (d) TRIM29 staining in moderately differentiated pancreatic adenocarcinoma but not in adjacent normal pancreatic ductal cells. (e) Higher magnification of the delineated inset of (d) image. (f) TRIM29 staining in well-differentiated pancreatic adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4016900&req=5

fig1: TRIM29 is overexpressed in the pancreatic cancer cells by immunohistochemical analysis. (a) Adjacent nontumor pancreatic duct (NPD) is indicated. (b) Malignant pancreatic duct shows nuclear TRIM29 staining, whereas adjacent pancreatic ductal cells show negative staining. Pancreatic cancer cells (PC) are indicated. (c) TRIM29 staining in poorly differentiated pancreatic adenocarcinoma. (d) TRIM29 staining in moderately differentiated pancreatic adenocarcinoma but not in adjacent normal pancreatic ductal cells. (e) Higher magnification of the delineated inset of (d) image. (f) TRIM29 staining in well-differentiated pancreatic adenocarcinoma.

Mentions: By immunohistochemical staining carriedout in 186 pancreatic tumors and matched adjacent nontumor pancreatictissues, we found weak cytoplasmic TRIM29 expression in nontumor pancreatic ductal cells (Figure 1(a)). In contrast, TRIM29 showed predominantly nuclear immunostaining in well, moderate, and poorly differentiated carcinomas (Figures 1(b)–1(f)). According to semiquantitative assessment, TRIM29 positivity was 58.6% (109/186) in pancreatic cancers and 8.6% (16/186) in pairednontumor pancreatic tissues, which was statistically different (P < 0.001).


TRIM29 as a novel biomarker in pancreatic adenocarcinoma.

Sun H, Dai X, Han B - Dis. Markers (2014)

TRIM29 is overexpressed in the pancreatic cancer cells by immunohistochemical analysis. (a) Adjacent nontumor pancreatic duct (NPD) is indicated. (b) Malignant pancreatic duct shows nuclear TRIM29 staining, whereas adjacent pancreatic ductal cells show negative staining. Pancreatic cancer cells (PC) are indicated. (c) TRIM29 staining in poorly differentiated pancreatic adenocarcinoma. (d) TRIM29 staining in moderately differentiated pancreatic adenocarcinoma but not in adjacent normal pancreatic ductal cells. (e) Higher magnification of the delineated inset of (d) image. (f) TRIM29 staining in well-differentiated pancreatic adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4016900&req=5

fig1: TRIM29 is overexpressed in the pancreatic cancer cells by immunohistochemical analysis. (a) Adjacent nontumor pancreatic duct (NPD) is indicated. (b) Malignant pancreatic duct shows nuclear TRIM29 staining, whereas adjacent pancreatic ductal cells show negative staining. Pancreatic cancer cells (PC) are indicated. (c) TRIM29 staining in poorly differentiated pancreatic adenocarcinoma. (d) TRIM29 staining in moderately differentiated pancreatic adenocarcinoma but not in adjacent normal pancreatic ductal cells. (e) Higher magnification of the delineated inset of (d) image. (f) TRIM29 staining in well-differentiated pancreatic adenocarcinoma.
Mentions: By immunohistochemical staining carriedout in 186 pancreatic tumors and matched adjacent nontumor pancreatictissues, we found weak cytoplasmic TRIM29 expression in nontumor pancreatic ductal cells (Figure 1(a)). In contrast, TRIM29 showed predominantly nuclear immunostaining in well, moderate, and poorly differentiated carcinomas (Figures 1(b)–1(f)). According to semiquantitative assessment, TRIM29 positivity was 58.6% (109/186) in pancreatic cancers and 8.6% (16/186) in pairednontumor pancreatic tissues, which was statistically different (P < 0.001).

Bottom Line: TRIM29 protein expression was significantly correlated with lymph node metastasis (P = 0.019).Patients with positive TRIM29 expression showed both shorter overall survival and shorter recurrence-free survival than those with negative TRIM29 expression.Our results indicate that TRIM29 promotes tumor progression and may be a novel prognostic marker for pancreatic ductal adenocarcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Biliary and Vascular Surgery, Shengjing Hospital of China Medical University, Heping District, Shenyang 110004, China.

ABSTRACT

Background and aim: Tripartite motif-containing 29 (TRIM29) is structurally a member of the tripartite motif family of proteins and is involved in diverse human cancers. However, its role in pancreatic cancer remains unclear.

Methods: The expression pattern of TRIM29 in pancreatic ductal adenocarcinoma was assessed by immunocytochemistry. Multivariate logistic regression analysis was used to investigate the association between TRIM29 and clinical characteristics. In vitro analyses by scratch wound healing assay and invasion assays were performed using the pancreatic cancer cell lines.

Results: Immunohistochemical analysis showed TRIM29 expression in pancreatic cancer tissues was significantly higher  (n = 186) than that in matched adjacent nontumor tissues. TRIM29 protein expression was significantly correlated with lymph node metastasis (P = 0.019). Patients with positive TRIM29 expression showed both shorter overall survival and shorter recurrence-free survival than those with negative TRIM29 expression. Multivariate analysis revealed that TRIM29 was an independent factor for pancreatic cancer over survival (HR = 2.180, 95% CI: 1.324-4.198, P = 0.011). In vitro, TRIM29 knockdown resulted in inhibition of pancreatic cancer cell proliferation, migration, and invasion.

Conclusions: Our results indicate that TRIM29 promotes tumor progression and may be a novel prognostic marker for pancreatic ductal adenocarcinoma.

Show MeSH
Related in: MedlinePlus